Advertisement
Table 3 Secondary outcomes at final follow-up
| Outcome | Number of event (%) | Statin vs. non-statin | ||
|---|---|---|---|---|
| Statin (n = 441) | Non-statin (n = 441) | HR (95% CI) | P value | |
| All-cause mortality | 250 (56.7) | 271 (61.5) | .70 (.59, .84) | <.001 |
| Hemorrhage stroke | 4 (.9) | 2 (.5) | 1.23 (.22, 6.84) | .810 |
| Heart failure | 59 (13.4) | 44 (10.0) | 1.08 (.73, 1.60) | .714 |
| Acute hepatitis | 1 (.2) | 3 (.7) | .22 (.02, 2.16) | .194 |
| Rhabdomyolysis | 4 (.9) | 1 (.2) | 3.36 (.38, 30.06) | .279 |
| Newly diagnosed dementia | 0 (.0) | 1 (.2) | NA | NA |
| Newly diagnosed malignancy | 14 (3.2) | 9 (2.0) | 1.09 (.46, 2.56) | .844 |
